A single dose of UX111 (rebisufligene etisparvovec), an experimental gene therapy being developed by Ultragenyx Pharmaceutical, reduces the toxic buildup of heparan sulfate for more than eight years and helps children with Sanfilippo syndrome type A maintain or improve developmental skills, particularly when administered early. These long-term results…